Annual Results 2022 - Feb 01, 2023

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Webcast and presentation

Watch the webcast

Download the presentation (PDF 5.1 MB)

Download the podcast (MP3 45 MB)  

Read the presentation transcript

Novartis ESG Update Q4 2022 (PDF 0.9 MB)
 

Annual Report and US Securities & Exchange Commission Form 20-F

These reports, filed with the SIX Swiss Exchange in Switzerland and the US Securities and Exchange Commission (SEC) in the US, provide a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. They also disclose our operating and financial results, accompanied by audited annual financial statements.

Download the Novartis Annual Report 2022 (SIX filing) (PDF 3.9 MB)

Download the Novartis Form 20-F/A 2022 (SEC filing) (PDF 3.8 MB)

To request a hard copy of the Annual Report and/or SEC Form 20-F, fill out the order form.

Annual Results 2022 - Feb 01, 2023

Key figures1 FY 2022
(USD m)		 FY 2021
(USD m)		 % change
(USD/cc)
Net sales 50,545 51,626 -2 (cc: 4)
Operating income 9,197 11,689 -21 (cc: -13)
Net income 6,955 24,018 -71 (cc: -67)
EPS (USD) 3.19 10.71 -70 (cc: -66)
Free cash flow 11,945 13,282 -10

Core		      
Operating income 16,665 16,588 0 (cc: 8)
Net income 13,352 14,094 -5 (cc: 3)
EPS (USD) 6.12 6.29 -3 (cc: 6)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Watch the webcast

Download the presentation (PDF 5.1 MB)

Download the podcast (MP3 45 MB)

Read the presentation transcript

Novartis ESG Update Q4 2022 (PDF 0.9 MB)

Annual Results 2021 - Feb 02, 2022

Key figures1 FY 2021
(USD m)		 FY 2020
(USD m)		 % change
(USD/cc)
Net sales 51,626 48,659 6 (cc: 4)
Operating income 11,689 10,152 15 (cc: 13)
Net income 24,018 8,071 198 (cc: 195)
EPS (USD) 10.71 3.55 202 (cc: 200)
Free cash flow 13,282 11,691 14

Core		      
Operating income 16,588 15,416 8 (cc: 6)
Net income 14,094 13,158 7 (cc: 5)
EPS (USD) 6.29 5.78 9 (cc: 7)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Download the podcast (MP3 43 MB)

Read the presentation transcript

Download the presentation (PDF 4.9 MB)

Novartis ESG Update - February 03, 2022 (PDF 1.7 MB)

Annual Results 2020 - Jan 26, 2021

Key figures2 Continuing operations1
  FY 2020
(USD m)		 FY 2019
(USD m)		 % change
(USD/cc)
Net sales 48,659 47,445 3 (cc: 3)
Operating income 10,152 9,086 12 (cc: 19)
Net income 8,071 7,147 13 (cc: 20)
EPS (USD) 3.55 3.12 14 (cc: 21)
Free cash flow 11,691 12,937 -10

Core		      
Operating income 15,416 14,112 9 (cc: 13)
Net income 13,158 12,104 9 (cc: 12)
EPS (USD) 5.78 5.28 9 (cc: 13)
  1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)

Condensed financial report (PDF 0.6 MB)

Read the presentation transcript

Download the podcast (MP3 45 MB)

Download the presentation (PDF 3.6 MB)

Annual Results 2019 - Jan 29, 2020

Key figures2 Continuing operations1
  FY 2019
(USD m)		 FY 2018
(USD m)		 % change
(USD/cc)
Net sales 47,445 44,751 6 (cc: 9)
Operating income 9,086 8,403 8 (cc: 14)
Net income 7,147 12,800 -44 (cc: -41)
EPS (USD) 3.12 5.52 -43 (cc: -40)
Free cash flow 12,937 11,256 15

Core		      
Operating income 14,112 12,557 12 (cc: 17)
Net income 12,104 10,920 11 (cc: 15)
EPS (USD) 5.28 4.71 12 (cc: 17)
  1. Refers to continuing operations as defined on page 45 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.1 MB) | Deutsch (PDF 0.1 MB) | Français (PDF 0.1 MB)

Condensed financial report (PDF 0.6 MB)

Annual Results 2018 - Jan 30, 2019

Key figures1 FY 2018
(USD m)		 FY 2017
(USD m)		 % change
(USD/cc)
Net sales 51,900 49,109 6 (cc: 5)
Operating income 8,169 8,629 -5 (cc: -5)
Net income 12,614 7,703 64 (cc: 64)
EPS (USD) 5.44 3.28 66 (cc: 66)
Free cash flow 11,717 10,428 12

Core		      
Operating income 13,823 12,850 8 (cc: 8)
Net income 11,938 11,391 5 (cc: 5)
EPS (USD) 5.15 4.86 6 (cc: 6)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Media release

English (PDF 0.1 MB) | Deutsch (PDF 0.1 MB) | Français (PDF 0.2 MB)

Condensed financial report (PDF 0.6 MB)

XBRL package

Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).

XBRL Package (ZIP 0.7 MB)

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.